Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase II Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases

The study will enroll approximately 120 patients in a multi-center, controlled, randomized, double-masked trial assessing the safety and efficacy of KIO-101 eye drops in patients living with autoimmune disease who have signs and symptoms of ocular surface disease.